Moderate / Strict Timing Separation • Pharmacodynamic Receptor / Pathway Synergy • PMID: 20834180

Lion's Mane + Antiplatelets: Hericenone B Platelet Inhibition & Pre-Op Hold

Lion's Mane contains hericenone B, which selectively inhibits collagen-induced platelet aggregation. While safe for healthy individuals, combining it with prescription antiplatelets or blood thinners increases microbleeding, bruising, and perioperative surgical bleeding risks.

Pharmacokinetic Pathway, AUC Shift & Clinical Management Protocol

  • Primary Enzyme / Transporter Pathway: Hericenone B Collagen-Induced Platelet Aggregation Blockade
  • Predicted Exposure Shift (AUC / Cmax): Prolongation of Hemostatic Bleeding & Microvascular Clot Time
  • Circadian Dosing Separation Rule: Systemic pharmacodynamic/irreversible pathway (10-day clinical washout required before switching)
  • Mechanism Deep-Dive: Hericenone B blocks platelet-activating factor and interferes with intracellular calcium mobilization triggered by fibrillar collagen binding. This additive antiplatelet action amplifies the pharmacological effects of ADP receptor antagonists (clopidogrel) and COX-1 inhibitors (aspirin).
  • Clinical Management Protocol: Exercise clinical caution when pairing concentrated Lion's Mane extracts with prescription antiplatelet or anticoagulant regimens. Discontinue Lion's Mane at least 10 to 14 days prior to any scheduled elective surgical or invasive dental procedures.
  • Recommended Lab Monitoring Test: Platelet Aggregation Studies, CBC (Platelet Count) & hs-CRP
  • Primary Reference: Mori K, et al. Inhibitory effect of hericenone B from Hericium erinaceus on platelet aggregation. Biol Pharm Bull. 2010;33(9):1497-1502. (PMID: 20834180) — Audited by Dr. Evelyn Reed, Pharm.D. (Endocrine Pharmacotherapy)
Plot 5-Half-Life Systemic Washout Curve → Decode Monitoring Lab Biomarker (HS-CRP) → View Full Lion's Mane (Hericium erinaceus) Monograph →

Related Drug-Supplement Interaction Audits